About
Saudi biotechnology accelerator
Currently, Europe and the US lead in regulatory compliance for Medical, Pharma and Clinical Affairs. Saudi Arabia seeks to address a need for such capability in the National Biotechnology Strategy published in January 2024, which specifically calls for “Regulatory excellence”.
Regulatory compliance is effectively what the whole strategy is based upon. This is a specialist area in which Saudi Arabia has a known gap that is currently not being addressed and is impeding all other activities related to Biotechnology, MedTech, and Pharmaceutical initiatives.
All Care Group (Saudi) and Evnia (Denmark) have come together to develop a Joint Venture (ARETI) which will create the largest Biotechnology Accelerator in the MENA. ARETI will be a cornerstone for the delivery of the National Biotechnology Strategy through Saudi Biotechnology Accelerator and ARETI Investments.
“An inspiring quote about your vision”
Your Name
As Featured In
This is a space to showcase any publications your work has been featured in
A Title That Gets the Visitor to Contact You
This is your chance to emphasize why the visitor should contact you right now.
Saudi Biotechnology Accelerator
Commercializing Early-Stage Biotechnology Innovation Through Regulatory Excellence